Biology of Blood and Marrow Transplantation
Volume 14, Issue 1 , Pages 59-66 , January 2008

Dose-Reduced Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation for Human Immunodeficiency Virus–Associated Lymphoma: AIDS Malignancy Consortium Study 020

  • Thomas R. Spitzer

      Affiliations

    • Massachusetts General Hospital
    • Corresponding Author InformationCorrespondence and reprint requests: Address correspondence to: Thomas R. Spitzer, MD, Bone Marrow Transplant Program, Massachusetts General Hospital, 0 Emerson Place, Suite 118, 55 Fruit Street, Boston, MA 02114
    • ,
  • Richard F. Ambinder

      Affiliations

    • Johns Hopkins University School of Medicine
    • ,
  • Jeannette Y. Lee

      Affiliations

    • University of Alabama
    • ,
  • Lawrence D. Kaplan

      Affiliations

    • University of California San Francisco
    • ,
  • William Wachsman

      Affiliations

    • University of California San Diego/VA San Diego Healthcare System
    • ,
  • David J. Straus

      Affiliations

    • Memorial Sloan Kettering Cancer Center
    • ,
  • David M. Aboulafia

      Affiliations

    • Virginia Mason Medical Center
    • ,
  • David T. Scadden

      Affiliations

    • Massachusetts General Hospital

Received 16 September 2006 ,Accepted 19 March 2007.

References 

  1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;323:1540–1545
  2. Lin TS, Copelan EA. Autologous stem cell transplantation for non-Hodgkin's lymphoma. Curr Hematol Rep. 2003;2:310–315
  3. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359:2065–2071
  4. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–1054
  5. Navarro WH, Kaplan LD. AIDS-related lymphoproliferative disease. Blood. 2006;107:13–20
  6. Clayton A, Mughal T. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy in the post–highly active antiretroviral therapy era?. Hematol Oncol. 2004;22:111–120
  7. Bower M, Gazzard B, Mandalia S, et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med. 2005;143:265–273
  8. Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin's lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006;107:3832–3840
  9. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002;100:1984–1988
  10. Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival. Results of the German Multicenter Trial. Cancer. 2006;106:1560–1568
  11. Lim ST, Levine AM. Non-AIDS–defining cancers and HIV infection. Curr HIV/AIDS Rep. 2005;2:146–153
  12. Straus DJ. HIV-associated lymphoma: promising new results, but with toxicity. Blood. 2005;105:1842
  13. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005;105:874–878
  14. Serrano D, Carrion R, Balsalobre P, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol. 2005;33:487–494
  15. Gabarre J, Marcelin AG, Azar N, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica. 2004;89:1100–1108
  16. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol. 2003;21:4423–4427
  17. Wood C, Harrington W. AIDS and associated malignancies. Cell Res. 2005;15:947–952
  18. Spitzer TR, Cox B, Sepe P, et al. Dose adjusted busulfan/cyclophosphamide and autologous stem cell transplantation for recurrent lymphoma. Blood. 2004;104:522a
  19. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849
  20. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244
  21. Benicchi T, Ghidini C, Re A, et al. T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation. 2005;80:673–682
  22. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347–1353
  23. Santos GW. The development of busulfan/cyclophosphamide preparative regimens. Semin Oncol. 1993;20:12–17
  24. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55–61
  25. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055–3060
  26. Olavarria E, Hassan M, Eades A, et al. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia. 2000;14:1954–1959
  27. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;8:493–500
  28. Lee JH, Choi SJ, Kim SE, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol. 2005;84:321–330
  29. Andersson BS, Madden T, Tran HT, et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000;6:548–554
  30. Kiss TL, Panzarella T, Messner HA, et al. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2003;31:73–78
  31. de Magalhaes-Silverman M, Lister J, Rybka W, et al. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant. 1997;19:777–781
  32. Avalos BR, Klein JL, Kapoor N, et al. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY. Bone Marrow Transplant. 1993;12:133–138
  33. Vose JM, Rizzo DJ, Tao-Wu J, et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant. 2004;10:116–127
  34. Lazarus HM, Loberiza FR, Zhang MJ, et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001;27:387–396

PII: S1083-8791(07)00460-0

doi: 10.1016/j.bbmt.2007.03.014

Biology of Blood and Marrow Transplantation
Volume 14, Issue 1 , Pages 59-66 , January 2008

Article Tools

* Image Usage & Resolution